Literature DB >> 18381417

Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Nathalie Dourdin1, Babette Schade, Robert Lesurf, Michael Hallett, Robert J Munn, Robert D Cardiff, William J Muller.   

Abstract

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and amplification or elevated expression of ErbB-2 are both involved in human breast cancer. To directly test the importance of these genetic events in mammary tumorigenesis, we have assessed whether mammary-specific disruption of PTEN could cooperate with activation of ErbB-2. Transgenic mice expressing ErbB-2 under the transcriptional control of its endogenous promoter (ErbB-2(KI)) were interbred with mice carrying conditional PTEN alleles and an MMTV/Cre transgene. Loss of one or both PTEN alleles resulted in a dramatic acceleration of mammary tumor onset and an increased occurrence of lung metastases in the ErbB-2(KI) strain. Tumor progression in PTEN-deficient/ErbB-2(KI) strains was associated with elevated ErbB-2 protein levels, which were not due to ErbB-2 amplification or to a dramatic increase in ErbB-2 transcripts. Moreover, the PTEN-deficient/ErbB-2(KI)-derived mouse mammary tumors display striking morphologic heterogeneity in comparison with the homogeneous pathology of the ErbB-2(KI) parental strain. Therefore, inactivation of PTEN would not only have a dramatic effect on ErbB-2-induced mammary tumorigenesis but would also lead to the formation of mammary tumors that, in part, display pathologic and molecular features associated with the basal-like subtype of primary human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381417      PMCID: PMC2752841          DOI: 10.1158/0008-5472.CAN-07-5727

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.

Authors:  D Dankort; B Maslikowski; N Warner; N Kanno; H Kim; Z Wang; M F Moran; R G Oshima; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu.

Authors:  Cristina Montagna; Eran R Andrechek; Hesed Padilla-Nash; William J Muller; Thomas Ried
Journal:  Oncogene       Date:  2002-01-31       Impact factor: 9.867

4.  Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN.

Authors:  J J Scarisbrick; A J Woolford; R Russell-Jones; S J Whittaker
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

Review 5.  PTEN, a unique tumor suppressor gene.

Authors:  P L Dahia
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

6.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

7.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Authors:  Lao H Saal; Sofia K Gruvberger-Saal; Camilla Persson; Kristina Lövgren; Mervi Jumppanen; Johan Staaf; Göran Jönsson; Maira M Pires; Matthew Maurer; Karolina Holm; Susan Koujak; Shivakumar Subramaniyam; Johan Vallon-Christersson; Håkan Olsson; Tao Su; Lorenzo Memeo; Thomas Ludwig; Stephen P Ethier; Morten Krogh; Matthias Szabolcs; Vundavalli V V S Murty; Jorma Isola; Hanina Hibshoosh; Ramon Parsons; Ake Borg
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

8.  Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.

Authors:  Andrea Rosner; Keiko Miyoshi; Esther Landesman-Bollag; Xin Xu; David C Seldin; Amy R Moser; Carol L MacLeod; G Shyamala; Amy E Gillgrass; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

9.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

Authors:  E R Andrechek; W R Hardy; P M Siegel; M A Rudnicki; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland.

Authors:  Gang Li; Gertraud W Robinson; Ralf Lesche; Hilda Martinez-Diaz; Zhaorong Jiang; Nora Rozengurt; Kay-Uwe Wagner; De-Chang Wu; Timothy F Lane; Xin Liu; Lothar Hennighausen; Hong Wu
Journal:  Development       Date:  2002-09       Impact factor: 6.868

View more
  22 in total

1.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

Review 2.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

3.  PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Authors:  Howard M Stern; Humphrey Gardner; Tomasz Burzykowski; Wafaa Elatre; Carol O'Brien; Mark R Lackner; Gary A Pestano; Angela Santiago; Ivonne Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Paolo Nuciforo; Valerie Bee; John Mackey; Dennis J Slamon; Michael F Press
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

4.  Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.

Authors:  Saya H Ebbesen; Maurizio Scaltriti; Carl U Bialucha; Natasha Morse; Edward R Kastenhuber; Hannah Y Wen; Lukas E Dow; José Baselga; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

5.  β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.

Authors:  Tung Bui; Babette Schade; Robert D Cardiff; Olulanu H Aina; Virginie Sanguin-Gendreau; William J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 6.  Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Toxicol Pathol       Date:  2010-01-15       Impact factor: 1.902

Review 7.  Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.

Authors:  Julie A Wickenden; Christine J Watson
Journal:  Breast Cancer Res       Date:  2010-04-09       Impact factor: 6.466

Review 8.  Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.

Authors:  Eran R Andrechek; Joseph R Nevins
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

9.  Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.

Authors:  Guillaume Banneau; Mickaël Guedj; Gaëtan MacGrogan; Isabelle de Mascarel; Valerie Velasco; Renaud Schiappa; Valerie Bonadona; Albert David; Catherine Dugast; Brigitte Gilbert-Dussardier; Olivier Ingster; Pierre Vabres; Frederic Caux; Aurelien de Reynies; Richard Iggo; Nicolas Sevenet; Françoise Bonnet; Michel Longy
Journal:  Breast Cancer Res       Date:  2010-08-16       Impact factor: 6.466

10.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.